Ireland-based Avadel Pharmaceuticals, a developer of central nervous system therapies, has seen a 2.24% stake disclosed by US investment firm Geode Capital Management, according to a regulatory filing with the Irish Takeover Panel.

The disclosure, filed through Form 8.3, confirmed Geode Capital holds 2,187,635 ordinary shares in Avadel as of 13 November 2025. The filing also reported a recent purchase of 1,164 additional shares at $19.24 (€16.60) per unit, reflecting ongoing interest from institutional investors.

The filing comes under Rule 8.3 of the Irish Takeover Panel Act, which requires public reporting of positions representing 1% or more of a company’s securities during offer periods. Geode confirmed it has no cash-settled derivatives, stock-settled derivatives, or indemnity arrangements relating to Avadel securities.

Avadel Pharmaceuticals, headquartered in Dublin, focuses on pharmaceutical products targeting central nervous system conditions. The company’s operations and portfolio development remain under scrutiny from both the investment community and regulatory authorities, as the disclosure demonstrates growing visibility of institutional stakes in the Irish pharma sector.

The regulatory filing underlines the structured monitoring of ownership in public pharmaceutical companies, ensuring transparency in shareholding changes and compliance with Irish Takeover Panel rules. It also provides insight into the investment trends and confidence levels among global asset managers in emerging and established pharma businesses based in Ireland.

As Avadel continues to develop therapies for neurological conditions, this stake by Geode Capital reflects both the company’s market position and the wider investor appetite for pharmaceutical innovation originating in Europe.

Monitor Avadel’s ownership developments and strategic updates by reading the full story.